RT Journal Article
SR Electronic
T1 Crykey: Rapid Identification of SARS-CoV-2 Cryptic Mutations in Wastewater
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.16.23291524
DO 10.1101/2023.06.16.23291524
A1 Liu, Yunxi
A1 Sapoval, Nicolae
A1 Gallego-García, Pilar
A1 Tomás, Laura
A1 Posada, David
A1 Treangen, Todd J.
A1 Stadler, Lauren B.
YR 2023
UL http://medrxiv.org/content/early/2023/11/12/2023.06.16.23291524.abstract
AB We present Crykey, a computational tool for rapidly identifying cryptic mutations of SARS-CoV-2. Specifically, we identify co-occurring single nucleotide mutations on the same sequencing read, called linked-read mutations, that are rare or entirely missing in existing databases, and have the potential to represent novel cryptic lineages found in wastewater. While previous approaches exist for identifying cryptic linked-read mutations from specific regions of the SARS-CoV-2 genome, there is a need for computational tools capable of efficiently tracking cryptic mutations across the entire genome and for tens of thousands of samples and with increased scrutiny, given their potential to represent either artifacts or hidden SARS-CoV-2 lineages. Crykey fills this gap by identifying rare linked-read mutations that pass stringent computational filters to limit the potential for artifacts. We evaluate the utility of Crykey on >3,000 wastewater and >22,000 clinical samples; our findings are three-fold: i) we identify hundreds of cryptic mutations that cover the entire SARS-CoV-2 genome, ii) we track the presence of these cryptic mutations across multiple wastewater treatment plants and over a three years of sampling in Houston, and iii) we find a handful of cryptic mutations in wastewater mirror cryptic mutations in clinical samples and investigate their potential to represent real cryptic lineages. In summary, Crykey enables large-scale detection of cryptic mutations representing potential cryptic lineages in wastewater.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Houston Health Department, Centers for Disease Control (CDC) contracts 75D30121C11180 and 75D30122C14709, P01-AI152999 NIH award, and by National Science Foundation (NSF) grants EF-2126387, IIS-2239114, CNS-1338099, CBET 2029025, and seed funds from Rice University and the City of Houston.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes